Novogen of Australia Reports Favorable Trial For Pancreatic Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Australia's Novogen said it received favorable reports from trials on its triphendiol for treating pancreatic cancer. The drug was tried in combination with Eli Lilly's Gemzar (gemcitabine hydrochloride). The Sydney-based company recently announced positive results for its promensil product for maintaining ovarian cancer remission in addition to its use for treating menopausal symptoms. (Click here for more
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.